Navigation Links
Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA
Date:7/31/2009

EXTON, Pa., July 31 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the wave one LaunchTrends(TM): SIMPONI and CIMZIA report. The survey was completed by U.S. Rheumatologists in late June 2009.

While awareness of both new TNF antagonists is relatively high, there are some troubling signs regarding initial impressions of these agents. The initial favorability rating for Simponi, for example, has slipped from 65% in the baseline report to 41% with the current wave of research. The initial favorability rating for Cimzia was significantly lower than both the baseline and current results for Simponi.

More than one-half of surveyed physicians have prescribed Simponi while less than one-third report trial of Cimzia. Over 80% of Simponi patients were switched from other biologics (primarily Humira) while a higher percent of the Cimzia patients were biologic naive. The majority of Rheumatologists see both of these agents as second or third line biologic options for the treatment of RA.

Dosing with Cimzia appears to be both a blessing and a curse -- once monthly administration has high patient appeal, but the loading dose, large volume, two injection requirement, and potential patient confusion are also noted as product disadvantages. Simponi is viewed as being significantly easier to administer. The Rheumatologists surveyed, however, view the products as extremely similar. While both Simponi and Cimzia are expected to gain market share in the next six months, the combined share of the two agents is not expected to exceed 15% of the biologic share in Rheumatoid Arthritis.

Looking to the future, Rheumatologists report high familiarity with Roche's ACTEMRA, an IL-6 blocker in Phase III clinical trials. Unlike the established TNFs (Enbrel, Humira, and Remicade) which have been the target of Cimzia and Simponi's launches, the survey respondents anticipate that Actemra would be most likely to replace BMS's Orencia in their practices.

LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at three months post launch, will be fielded on August 17. The results will be published in mid-September.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crowded emergency departments pose greater risks for patients with heart attacks
2. Crowded Households Raise Womens Heart Risk
3. Osteotech to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
4. Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment
5. Air Methods to Report Second Quarter Financial Results After Market Close on Thursday, August 6, 2009
6. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
7. Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009
8. Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market
9. NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
10. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
11. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... , ... May 26, 2017 , ... ... at Boston CEO 2017 on May 30th and 31st at The Four Seasons ... for leading executives in the life sciences, offering exclusive access to key decision ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Amir ... Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS ... , “We are pleased to be the first in Arkansas to introduce the most ...
(Date:5/26/2017)... Minneapolis, MN (PRWEB) , ... May 26, 2017 , ... ... five U.S. states with the healthiest seniors are located in the Midwest. With the ... 2060, more and more people are concerned with both the quality and affordability of ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... ... 2017 , ... After raising nearly $30,000 on Kickstarter , about three-times ... at a discounted crowdfunding price on Indiegogo . , “Along with creating an ... to bring a fidget toy to the market that was made of superior quality ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
(Date:5/10/2017)... 10, 2017 CSSi, the global leader in ... research industry, is proud to announce the launch of ... website features both enriched content and a customized layout ... the company,s already well-established position as the top global ... "After many months of hard work, we are delighted ...
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
Breaking Medicine Technology: